Ideaya Biosciences falls -11.8%
Ideaya Biosciences (IDYA) is down -11.8%, or -$3.57 to $26.79.
Fiscal Year: January - December
IDEAYA Biosciences, Inc. (IDYA), listed on the NASDAQ, has a market capitalization of $2.53B. As of Nov 20, 2026, the stock is trading at $26.17 per share@else an unavailable price , offering investors a clear view of its current market value. IDEAYA Biosciences, Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of N/A , investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. IDEAYA Biosciences, Inc. also offers a dividend yield of N/A , making it an attractive option for income-focused investors who seek regular dividends.
DCF analysis data is not yet available for IDEAYA Biosciences, Inc. (IDYA). A fair value is shown for companies with at least three years of reported free cash flow and a positive typical free cash flow margin. Banks, insurers and REITs need a different valuation model and are not covered yet.
The proprietary SS Score for IDEAYA Biosciences, Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for IDEAYA Biosciences, Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for IDEAYA Biosciences, Inc. is N/A , offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, IDEAYA Biosciences, Inc. (IDYA) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether IDEAYA Biosciences, Inc. (IDYA) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. It is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of IDEAYA Biosciences, Inc. (IDYA) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of IDEAYA Biosciences, Inc.. To access the full SS Score, consider upgrading your subscription.
IDEAYA Biosciences, Inc. is a significant player in the industry sector, with a market capitalization of $2.53B and a competitive P/E ratio of N/A . Investors should compare these metrics with industry peers to gauge whether IDEAYA Biosciences, Inc. is outperforming or underperforming within its sector.
Ideaya Biosciences (IDYA) is down -11.8%, or -$3.57 to $26.79.
Ideaya announced its registrational strategy for IDE849, a potential best-in-class delta-like ligand 3 – DLL3-targeting Topo-I-payload antibody drug conjugate, or ADC, in previously treated neuroendoc...
Single-arm extension cohort of approximately 90 refractory GEP-NEC patients to support potential accelerated approval, with ORR by BICR as the primary endpoint Randomized Phase 3 trial in multiple ref...
IDEAYA Biosciences (IDYA) announced development candidate nomination of IDE101, a potential first-in-class dual cyclin-dependent kinase, CDK, inhibitor designed to address the loss of CDKN2A-mediated ...
Development candidate demonstrates encouraging preclinical activity in CDKN2A-deficienct tumor models as a monotherapy and in combination with inhibitors of RAS and MTAP, including IDEAYA's proprietar...
Mizuho lowered the firm’s price target on Ideaya Biosciences (IDYA) to $39 from $44 and keeps an Outperform rating on the shares following the Q3 report.
Citi raised the firm’s price target on Ideaya Biosciences (IDYA) to $66 from $65 and keeps a Buy rating on the shares.
RBC Capital lowered the firm’s price target on Ideaya Biosciences (IDYA) to $45 from $48 and keeps an Outperform rating on the shares after its Q3 results. All programs continue…
Wedbush raised the firm’s price target on Ideaya Biosciences (IDYA) to $63 from $60 and keeps an Outperform rating on the shares. The firm notes the company reported third quarter…
Guggenheim lowered the firm’s price target on Ideaya Biosciences (IDYA) to $52 from $57 and keeps a Buy rating on the shares.
SOUTH SAN FRANCISCO, Calif., Nov. 4, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeu...
Truist lowered the firm’s price target on Ideaya Biosciences (IDYA) to $57 from $59 and keeps a Buy rating on the shares. The company’s Q3 and the firm’s 1×1 with…
Reports Q3 revenue $10.24M, consensus $7.58M. “We are encouraged by the continued momentum at IDEAYA during the third quarter, marked by the successful completion of our first NDA filing for…
Data presented at ESMO 2026 collectively supports the potential of darovasertib to become a foundational new therapy across the treatment journey of uveal melanoma in both primary and metastatic disea...
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery, development and commercialization ...
Mizuho lowered the firm’s price target on Ideaya Biosciences (IDYA) to $44 from $50 and keeps an Outperform rating on the shares.
Ideaya Biosciences (IDYA) announced updated clinical results that show anti-tumor activity and preliminary overall survival results for IDE849, its investigational antibody-drug conjugate, or ADC, dir...
17.4-month median OS in 2L SCLC (n=51) and 14.7-month median OS in 2L + ≥3L SCLC (n=101) 72.5% (37/51) ORR and 60.8% (31/51) cORR in 2L SCLC with 6.9-month median PFS; 68.3% (69/101) ORR and 54.5% (55...
Ideaya Biosciences (IDYA) announced updated clinical data from three ongoing studies evaluating darovasertib in metastatic and primary uveal melanoma, or UM, that will be presented at the European Soc...
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.